A practical reference on Dihexa: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-06. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Males and females are affected equally. The disease was discovered in 1934 by Ivar Asbjørn Følling, with the importance of diet determined in 1935. As of 2023, genetic therapies that aim to directly restore liver PAH activity are a promising and active research field.
=== Affordable Care Act === Schmitt filed lawsuits to have the Affordable Care Act invalidated by courts. After Missouri voters approved a constitutional amendment to expand Medicaid coverage in the state, he argued that Republican lawmakers and Governor Mike Parson could legally refuse to implement the expansion. The Missouri Supreme Court rejected that position in a 2021 ruling.
== Pathophysiology == PSP affects those who come into contact with the affected shellfish by ingestion. The toxins responsible for most shellfish poisonings—mainly saxitoxin, although several other toxins have been found, such as neosaxitoxin and gonyautoxins I to IV—are water-insoluble, and heat- and acid-stable. Therefore, ordinary cooking methods will not eliminate the toxins. Symptoms typically appear within ten to 30 minutes after ingestion, and may include nausea, vomiting, diarrhea, abdominal pain, and tingling or burning lips, gums, tongue, face, neck, arms, legs, and toes. Shortness of breath, dry mouth, a choking feeling, confused or slurred speech, and loss of coordination are also possible. PSP toxins, such as saxitoxin, are able to bind near the sodium ion channel, blocking passage of potassium and/or sodium into (and out of) the cell. This restricts (or outright prevents) transmission of signals between neurons. This can result in (partial or complete) paralysis. PSP can be fatal in extreme cases, particularly in immunocompromised individuals; children are known to be more susceptible. Most shellfish can store saxitoxin for several weeks after a harmful algal bloom passes, but some, such as butter clams, can store the toxin for up to two years.
Sources: en.wikipedia.org
This gas flow passes through the centre of the plasma, where it forms a channel that is cooler than the surrounding plasma but still much hotter than a chemical flame. Samples to be analyzed are introduced into this central channel, usually as a mist of liquid formed by passing the liquid sample into a nebulizer. To maximise plasma temperature (and hence ionisation efficiency) and stability, the sample should be introduced through the central tube with as little liquid (solvent load) as possible, and with consistent droplet sizes. A nebuliser can be used for liquid samples, followed by a spray chamber to remove larger droplets, or a desolvating nebuliser can be used to evaporate most of the solvent before it reaches the torch. Solid samples can also be introduced using laser ablation. The sample enters the central channel of the ICP, evaporates, molecules break apart, and then the constituent atoms ionise. At the temperatures prevailing in the plasma a significant proportion of the atoms of many chemical elements are ionized, each atom losing its most loosely bound electron to form a singly charged ion. The plasma temperature is selected to maximise ionisation efficiency for elements with a high first ionisation energy, while minimising second ionisation (double charging) for elements that have a low second ionisation energy.
=== Essendon: 2008-2012 === Prismall returned from injury towards the second half of the 2009 season for the Essendon Bombers and had an injury free return. He played 13 games for the club in 2009 and was a regular contributor, kicking five goals. In the 2010 season, Prismall was in and out of the Essendon team. His performances were not consistent and his ball skills were lacking. Towards the end of the season, however, his form improved considerably, despite the team's poor performances on the field. After a reconstruction on his right knee in 2008, he injured his left knee in the opening minutes of round 19, 2011 match against Collingwood and was out for the rest of the season. Prismall was delisted at the end of the 2012 season.
From the late 1960s to the early 1970s, with the rapid surge in recreational drug use in the U.S., the production of narcotics in Mexico, particularly marijuana, expanded exponentially, and Mexican criminals started to smuggle drugs on a major scale. During the 1960s and 1970s, Mexico participated in a series of U.S.-backed anti-narcotics initiatives, including Operation Intercept and Operation Condor. These operations were formally justified on the grounds of combating the cultivation of opium poppies and marijuana in Mexico's so-called "Golden Triangle" region, an area encompassing parts of the states of Sinaloa, Durango, and Chihuahua. As part of the campaign, the Mexican government deployed about 10,000 soldiers and police. The operation resulted in mass arrests, torture, and imprisonment of peasants who were often accused of aiding leftist insurgency groups, but no major traffickers were captured. Contemporary assessments deemed the initiatives a failure, citing their inability to curb narcotics production, enabling military corruption, and their record of human rights abuses in rural areas. As U.S. efforts in the war on drugs intensified, crackdowns in Florida and the Caribbean during the Miami drug war forced Colombian traffickers to develop new routes for smuggling cocaine into the United States. By the early 1980s, the Medellin Cartel and Cali Cartel oversaw production, while distribution increasingly relied on Mexican traffickers.
Sources: en.wikipedia.org
== Early life and research == Hafezi was born in Remscheid, Germany in 1967, but he moved to Fribourg in Switzerland in 1981. He studied medicine in Fribourg and Bern, obtaining his Doctorate of Medicine at the Inselspital Bern under Prof. Dr. med Peter Weidmann, before going on in 1993, to undertake a two-year postgraduate course in Experimental Medicine and Biology at the University of Zürich. Hafezi spent three additional years at the University Hospital of Zurich, where he worked in the Laboratory for Retinal Cell Biology, which was part of the Department of Ophthalmology. Whilst studying in the Zürich laboratory, Hafezi identified the first known gene, c-Fos, that the absence of which could completely suppress light-induced apoptotic retinal degeneration. The group's findings were featured on the cover of the April 1997 edition of Nature Medicine. Hafezi then focused on a number of areas of cellular and retinal degeneration, in particular, light-induced photoreceptor death in the absence of p53 and JunD/AP-1, work that was published in IOVS and Cell Death & Differentiation, respectively. c-Fos and Fra1 are both components of the transcription factor AP-1, and in the year 2000, Hafezi and his colleagues presented work that showed that, in genetically engineered mice that express Fra1 where c-Fos is usually expressed, Fra1 can function in lieu of c-Fos to promote light-induced retinal photoreceptor death – work that was published in Genes & Development.
On the other hand, a fast reactor needs no moderator to slow down the neutrons at all, taking advantage of the fast neutrons producing a greater number of neutrons per fission than slow neutrons. For this reason ordinary liquid water, being a moderator and neutron absorber, is an undesirable primary coolant for fast reactors. Because large amounts of water in the core are required to cool the reactor, the yield of neutrons and therefore breeding of 239Pu are strongly affected. Theoretical work has been done on reduced moderation water reactors, which may have a sufficiently fast spectrum to provide a breeding ratio slightly over 1. This would likely result in an unacceptable power derating and high costs in a liquid-water-cooled reactor, but the supercritical water coolant of the supercritical water reactor (SCWR) has sufficient heat capacity to allow adequate cooling with less water, making a fast-spectrum water-cooled reactor a practical possibility. The type of coolants, temperatures, and fast neutron spectrum puts the fuel cladding material (normally austenitic stainless or ferritic-martensitic steels) under extreme conditions. The understanding of the radiation damage, coolant interactions, stresses, and temperatures are necessary for the safe operation of any reactor core. All materials used to date in sodium-cooled fast reactors have known limits. Oxide dispersion-strengthened alloy steel is viewed as the long-term radiation resistant fuel-cladding material that can overcome the shortcomings of today's material choices.
Based on MIC data and other studies, dalbavancin is more potent and bactericidal and therefore requires lower concentrations than vancomycin against these organisms. Dalbavancin also shows in vitro activity against vancomycin-susceptible Enterococcus faecium and Enterococcus faecalis. Other Gram-positive organisms belonging to the Bacillus spp., Listeria spp., and Corynebacterium spp. may show in vitro susceptibility, and dalbavancin may exhibit activity against enterococci expressing the VanB or VanC phenotype of acquired resistance against vancomycin. There is no clinically significant activity against Gram-negative bacteria.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.